- Previous Close
0.0202 - Open
0.0194 - Bid 0.0176 x --
- Ask 0.0578 x --
- Day's Range
0.0194 - 0.0194 - 52 Week Range
0.0096 - 0.0466 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
10.33M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, it develops tolerogens proteins technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
www.toleranzia.se10
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0EH.F
View MorePerformance Overview: 0EH.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0EH.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0EH.F
View MoreValuation Measures
Market Cap
10.76M
Enterprise Value
9.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.33
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.43%
Return on Assets (ttm)
-4.10%
Return on Equity (ttm)
-5.66%
Revenue (ttm)
30.03M
Net Income Avi to Common (ttm)
-9.44M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
13.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-38.42M